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It is well known that ion-pairing reagents cause ion suppression in LC-MS/MS methods. Here, we report that trichloroacetic acid
increases the MS signal of tobramycin. To support studies of an in vitro pharmacokinetic/pharmacodynamic simulator for
bacterial biofilms, an LC-MS/MS method for determination of tobramycin in M9 media was developed. Aliquots of 25 μL M9
media samples were mixed with the internal standard (IS) tobramycin-d5 (5 µg/mL, 25 µL) and 200 µL 2.5% trichloroacetic acid.
,e mixture (5 µL) was directly injected onto a PFP column (2.0× 50mm, 3 µm) eluted with water containing 20mM ammonium
formate and 0.14% trifluoroacetic acid and acetonitrile containing 0.1% trifluoroacetic acid in a gradient mode. ESI+ and MRM
with ion m/z 468→ 324 for tobramycin and m/z 473→ 327 for the IS were used for quantification. ,e calibration curve
concentration range was 50–25000 ng/mL. Matrix effect from M9 media was not significant when compared with injection
solvents, but signal enhancement by trichloroacetic acid was significant (∼3 fold). ,e method is simple, fast, and reliable. Using
the method, the in vitro PK/PD model was tested with one bolus dose of tobramycin.
1. Introduction
Tobramycin (TBM) is an aminoglycoside antibiotic widely
used for the treatment of multidrug-resistant Gram-negative
bacterial infections by inhibiting protein synthesis and al-
tering integrity of the bacterial cell membrane [1]. It is also
named 3′-deoxykanamycin B, nebramycin 6, and chemically
O-3-amino-3-deoxy-α-D-glucopyranosyl-(1-6)-O-[2,6-dia-
mino-2,3,6-trideoxy-α-D-ribo-hexopyranisyl-(1-4)]-2-deoxy-
D-streptamine (Figure 1). It is water soluble and stable at
ambient temperature at a wide range of pH 1–11 [2].
To support pharmacokinetic (PK) and pharmacodynamic
(PD) studies of TBM for biofilm-mediated infections using an
in vitromodel, an analytical method to quantitate TBM inM9
medium is needed. Two considerable challenges in de-
termination of TBM in biological matrices are (1) poor re-
tention on commonly used reverse-phase HPLC columns due
to its higher hydrophilicity and (2) lack of chromophores for
detection. Numerous assays have been reported including
HPLC coupled with UV [3], electrochemical [4, 5], or fluo-
rescence detectors [6], and these assays lack sensitivity and
usually require derivatization. LC-MS/MS assays have also
been reported, but the sensitivity of these assays requires
concentrations ≥100 ng/mL [7–9]. Trichloroacetic acid (TCA)
has been used in sample preparation to remove proteins, es-
pecially for hydrophilic analytes, with the advantage of direct
injection of resulting sample solution [10].We found thatTCA
not only increased the retention time but also theMS signal of
TBM.Built on this observation, we report a simple LC-MS/MS
method to determine TBM in M9 medium using TCA as the
ion pair reagent in the injection sample instead of the mobile
phase. In addition, this assay utilized a PFP column, which
yielded a better retention factor for TBM (k� 1.8). ,e cali-
bration range was 50–25000 ng/mL.
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2. Experimental
2.1. Chemicals and Reagents. Tobramycin was purchased
from Sigma-Aldrich (St. Louis, MO, USA). Deuterated
tobramycin (TBM-d5)was purchased fromTorontoResearch
Chemicals (North York, Ontario, Canada). Formulated
tobramycin (20mg/2mL, for IM or IV use) was obtained
from APP Pharmaceuticals, LLC (Schaumburg, IL, USA).
Common solvents (HPLC grade) and reagents (Certified
ACS)were obtained from,ermo-Fisher Sci. (Fair Lawn, NJ,
USA). M9 minimal salts ×5 solution was prepared by dis-
solving 2.82 g Difco™ M9 minimal salts (BD, Sparks, MD,
USA) in 50mL water. M9 medium was prepared by adding
10mL M9 minimal salts ×5 solution, 5 µL 1M CaCl2, 50 µL
1M MgSO4, and 13.5 µL 20% glucose to 40mL water.
2.2. Instrumental. ,e LC-MS/MS system consists of an AB
Sciex API5000 Tandem Mass Spectrometer, two Shimadzu
Prominence 20ADXR UFLC pumps, and an SIL-20ACXR
autosampler managed with Analyst® 1.6.2 (AB Sciex, Redwood
City,CA,USA).,egases for theMSsystemweresuppliedbyan
LC-MS gas generator (Source 5000™, Parker Balston Inc.,
Haverhill,MA,USA). LC conditionswere as follows: separation
was achieved on a Pursuit PFP column (2.1× 50mm, 3µm)
(AgilentTech. Inc., SantaClara,CA,USA).MobilephaseAwas
20mM NH4FA 0.14% trifluoroacetic acid (TFA) and B was
0.1% TFA in acetonitrile (MeCN). Five-microliter sample was
injected onto the column eluted at a flow rate of 0.4mL/min in
a gradient program consisting of 5% solvent B (0–0.10min),
from 5 to 20% B (0.10–1.50min), from 20 to 80% B (1.50–
1.51min), 80% B (1.51–2.00min), 80%–5% B (2.00–2.01min),
and 5% B (2.01–3.00min). Retention times for TBM and the
internal standard (IS) were both 0.84min.,edivert valve was
set to direct the LC eluent to the mass spectrometer (MS)
source at 0.6min and to the waste line at 2.9min. ,e MS
conditions for TBM and the IS were optimized by separate
infusion of 200 ng/mL TBM and 400 ng/mL deuterated TBM
in 0.1% formic acid into the MS at a flow rate of 15 and
25 µL/min constantly while adjusting MS parameters with
autotune followed by manual adjustment to achieve the
maximal signal. ,e ions m/z 468→ 324 for TBM and m/z
473→ 327 for the IS were used for quantification in the
multiple reaction monitoring (MRM) mode. ,e optimized
compound-dependentMSparameterswere 121V (DP), 21 V
(CE), and 26V (CXP) for both TBM and the IS. DP was
declustering potential, CEwas collision energy, andCXPwas
collision cell exit potential. ,e instrument-dependent pa-
rameters were optimized by flow injection analysis (FIA): an
aliquot of 5 µL 200 ng/mL TBM was repeatedly injected into
the LC-MS/MS system while LC flow was maintained at
0.4mL/min 50% B isocratically without column in the line.
,eoptimizedMSparameterswere as follows:MSsourcewas
the TurboIon Spray ionization in positive mode (ESI+) with
turbo heater set at 500°C, curtain gas was nitrogen at 40 psi,
nebulizer gas (gas 1) andauxiliary (Turbo) gas (gas 2)were zero
air set at 50 psi and 60 psi, respectively, collision-deactivated
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Figure 1: Product ion spectra of tobramycin (a) and deuterated tobramycin (b).
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associationgaswasnitrogen at 12 psi, and ionspray voltagewas
5500V. Data were processed with Analyst 1.6.2. (AB Sciex,
Redwood City, CA, USA).
2.3. Preparation of Calibrators, Quality Controls, and Internal
Standard. As TBM used in the in vitro biofilm PK/PD model
contains formulation ingredients, calibrators and quality
controls (QCs) were prepared from formulated TBM
(20mg/2mL) with serial dilution in M9 medium to match the
matrix inunknownsamples.Calibratorsconsistsof50,100,250,
500, 1000, 2500, 5000, 10000, and 25000ng/mL. QCs consist of
150, 1500, 20000, and 40000ng/mL, designated as low-, me-
dium-, high-, and extrahighQC.,e internal standardTBM-d5
solution was prepared in water by serial dilution at a final
concentration of 5000ng/mL.,e IS solution needs to standon
bench overnight before use.
2.4. Sample Preparation. M9 samples (25 µL) were pipetted
into 1mL glass autosampler vials, to which were added 25 µL
IS (5 µg/mL TBM-d5) and 200 µL 2.5% TCA. After vortex
mixed, the samples were placed in the autosampler tray. If
the samples were collected from M9 medium flowing
through bacterial biofilm, the samples were centrifuged at
20000g for 3min before adding to the sample vial. Injection
volume was 5 µL.
2.5. Validation. ,e method was validated in terms of
precision, accuracy, matrix effect, and stability, following the
procedures as described previously [10]. One set of cali-
brators was processed for each run and injected in the
beginning of the batch run. Calibration curves were con-
structed by linear regression of the peak area ratio of the
analyte to the IS (y-axis) versus the nominal analyte con-
centrations (x-axis) with a weighting factor of 1/x. ,e lower
limit of quantification (LLOQ) was established with pre-
cision and accuracy <20%. Intraday precision and accuracy
were determined by analysis of at least five replicates of each
QC sample at low (150 ng/mL), medium (1500 ng/mL), and
high (20000 ng/mL) concentration levels extracted with a set
of calibrators in one batch.,e same procedure was repeated
on at least 2 different days with new samples to determine
interday precision and accuracy (total: n≥ 15 per concen-
tration level). Precision was reported as relative standard
deviation (RSD) and accuracy as percent deviation from the
nominal concentration (% dev.). Matrix effect was evaluated
as follows: TBM was spiked at the concentrations of 300,
1500, and 20000 ng/mL in water and M9 medium, re-
spectively. ,ree aliquots of each sample were processed as
described above (Section 2.4). ,e peak areas and peak area
ratios of TBM in M9 medium were compared to those in
water. Values within 100± 15% were considered as no sig-
nificant matrix effect from M9 medium. To evaluate partial
volume accuracy, 12.5 µL extrahigh QC at 40000 ng/mL was
mixed with 12.5 µL M9 medium and processed as described
in Section 2.4. Stability was evaluated in the following
conditions: room temperature (21–25°C) for 5 days, 3 days
on the autosampler rack, 3 freeze-thaw cycles, and 6 days at
−70°C. Stability of freshly prepared IS working solution was
evaluated at room temperature for 24 hr and 5 days. Effects
of concomitant drugs (e.g., meropenem and colistin) on
quantification were evaluated by spiking them in the QC
samples at a final concentration of 110 µg/mL meropenem
(MP) and 20 µg/mL colistin.,emeasured concentrations of
TBM were compared to the QC samples without these
concomitant drugs.
2.6. Application. ,is method was used to validate a novel
dynamicPK/PDmodel designed to study the effects of human-
simulated antibiotic concentrations on Pseudomonas aerugi-
nosa biofilms grown in vitro [11]. TBM, in conjunction with
a β-lactam antibiotic such as MP, is recommended for the
treatment of multidrug-resistant Pseudomonas aeruginosa
lung infection in patients with cystic fibrosis [12]. While the
formation of bacterial biofilms in the lung is a characteristic of
chronic lung infection in patientswith cystic fibrosis, the PDof
antibiotics on biofilms is largely unknown.,e concentration-
time curves of single and multiple intravenous bolus doses of
TBM were simulated based on human population PK pa-
rameters [13]. ,e target TBM peak concentration, based on
a dose of 10mg/kg in a 70 kg adult, was 32.79mg/L with an
associated t1/2� 2.75 h. Samples were taken at t� 0, 1, 2, 4, 6, 8,
16, and 24 hr from the main feeding bottle and the tubing
outlets from three flow cells with bacterial biofilm. All samples
were shipped to our analytical lab on the same day with dry ice
overnight delivery and stored at −70°C freezer until analysis.
Samples were typically analyzed within a week.
3. Results and Discussion
3.1. LC-MS/MS Optimization. TBM contains five amine
groups (Figure 1), making electrospray ionization in positive
mode (ESI+) the choice of the ion source. ,e ion m/z
468→ 324 was chosen for quantification for its signal
abundancy and selectivity. Compared toproduct ionm/z163,
m/z 324 has less background signal.,e deuterated TBMwas
used as the IS. However, the deuteration positions were not
identified.MS scan showed thatmultiple forms of deuterated
TBM exist, with the most abundant protonated molecule at
m/z 473.,erefore, ionm/z 473→ 327 was chosen for the IS.
,e signal of the ionm/z473→ 327decreased gradually in the
first few hours but remained stable after the IS solution stood
on bench overnight. ,ese observations suggested that
deuteration most likely occurred on amine groups, and the
stable form of IS contains a deuterium atom on each amine
group (Figure 1).
Having 5 amine groups and 5 hydroxyl groups also
makes TBM hardly retain on reverse-phase LC columns. Ion
pair reagent TFA and TCA in the mobile phase could help to
retain polar amino molecules on the reverse-phase columns;
however, sensitivity may be compromised due to ion sup-
pression. Previously, we found that TFA could change re-
tention time of isoniazid when added into sample before
injection (Supplementary Material Figure S1). However,
TFA did not improve the TBMpeak. Cheng et al. used TCA to
modify retention time of aminoglycoside compounds [14].
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We found that when the sample contained 2% TCA with
a 5 µL injection volume, longer retention time of TBM
was observed (Supplementary Material Figure S2). Under
the final LC condition, the TBM peak was sufficiently sep-
arated from the matrix-generated peaks (Figure 2). ,e
retention time tR� 0.839min, the estimated dead volume is
0.68πr2L� 0.118mL, and retention factor k� 1.84.
Unexpectedly, TCA also enhancedMS response of TBM.
Two different sample solvents (water and 2% TCA) and two
sets of mobile phase solvents were tested: (1) A� 10mM
TBM
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Figure 2: Chromatograms of blank M9 medium (blue solid line), blank M9 medium spiked with IS (red dash line), and TBM at LLOQ level
(black solid line). (a) TBM channel; (b) the IS channel.
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Figure 3: Impact of mobile phase solvents and sample solvents on peak shape, retention time, and signal intensity of TBM. Sample solvents:
water (dash line) and 2% TCA (solid line). Mobile phase solvents: 10mMNH4FA (pH 4.0)-0.1% FA in MeCN (a) and 20mMNH4FA 0.14%
TFA-0.1% TFA in MeCN (b).
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NH4FA at pH 4.0; B� 0.1% FA in MeCN and (2) A� 20mM
NH4FA 1.4% TFA;, B� 0.1% TFA in MeCN, using the same
gradient elution method. With the commonly used mobile
phase solvents (set 1), the peak shape for TBM was poor if
injection solvent is water, while 2% TCA in the sample im-
proved peak shape, signal intensity, and retention time sig-
nificantly (Figure 3(a)); with mobile phase solvent set 2, the
signal intensity and retention time of TBM improved further
(Figure 3(b)).,is improvement is critical as the interference
peak from M9 medium was then separated from the TBM
peak (Figure 2).,e exactmechanism of signal enhancement
byTCA is unknown.Cheng et al. thought that reducedmatrix
effect with longer retention time contributed to the signal
enhancement [14], but we observed signal enhancement in
neat solution (Figure 3). ,e possible reason could be that
TCA limited multiple charges of TBM and thus increased
monocharged molecular ion ([M+H]+). In addition, we
observed that MS response of the IS (TBM-d5) was also in-
creased with the increase of TBM concentration, suggesting
ion enhancement of coeluting compounds. ,is should not
affect quantification as IS was added to all samples, and the
TBM signal increased accordingly. ,is was confirmed with
the excellent linearity of calibration curve.
3.2. Validation. Based on our initial simulation, the TBM
trough concentration is expected to be>250 ng/mL.,erefore,
the LLOQ in this assaywas initially set at 250 ng/mL, the upper
limit of quantification was set at 25000 ng/mL, and validation
was performed with low (300 ng/mL), medium (1500 ng/mL),
and high (20000 ng/mL) QCs. After tested the in vitro biofilm
model, we found that the troughTBMconcentration fell below
250 ng/mL, and thus, we lowered the LLOQ to 50 ng/mL and
the low QC level to 150 ng/mL accordingly. Validation of
intraday/interday precision and accuracy and interference of
concomitant drugs were repeated with the new low QC
concentration.
3.2.1. Calibration Range. At the LLOQ concentration
(50 ng/mL), the signal intensity was 2100–2400 cps (peak
area, 6600–7900) and signal-to-noise ratio S/N� 30–48
(Figure 2). ,is LLOQ is lower than others reported in lit-
erature. A recent study reported an LLOQ at 100 ng/mL.,e
detector was the same as ours, but heptafluorobutyric acid
was used as ion pair reagent in the mobile phase and sample
reconstitution [9].,ecalibration curvewas constructedwith
least square linear regression weighted by 1/x. ,e interday
backcalculated concentrations of calibrators over 3 days are
listed in Table 1. ,e precision is within 10% and accuracy
(percent deviation from the nominal value) is within ±10%,
too. Representative MRM ion chromatograms of TBM from
M9 medium (double blank), M9 medium spiked with IS
(blank), and LLOQ samples are shown in Figure 2.
3.2.2. Precision and Accuracy. ,e intraday precision (n� 6)
was within 7% at low, medium, and high concentrations.,e
interday precision, calculated with the individual mean
concentration from 3 days, was within 5% at the three
concentration levels.,e intra- and interday accuracy was all
within 15%. At the LLOQ levels, the precision and accuracy
met the criteria of <20% (Table 2).
3.2.3. Matrix Effect. ,e matrix effect of M9 medium on
both TBM and IS signals is within 100± 15% (Table 3),
suggesting that the matrix effect of M9 medium was not
significant. ,e matrix effect on the peak area ratio was
Table 1: Interday average backcalculated standard concentrations (n� 3).
Nominal concentration (ng/mL) 50 100 250 500 1000 2500 5000 10000 25000 R
Mean (ng/mL) 50.1 91.6 236 521 1043 2663 4973 9977 24800 0.9992
Precision (RSD, %) 3.82 6.11 3.31 2.98 3.37 2.50 8.06 3.72 2.91 0.0379
Accuracy (% dev.) 0.13 −8.37 −5.60 4.13 4.33 6.53 −0.53 −0.23 −0.80
n 3 3 3 3 3 3 3 3 3
Table 2: Intra- and interday precision and accuracy.
Intraday Interday
Nominal (ng/mL) 50.0 150 1500 20000 50.0 150 1500 20000
Mean (ng/mL) 43.0 to 50.9 150 to 159 1533 to 1653 20450 to 20650 46.8 153 1591 20572
Precision (RSD) (%) 3.0 to 16.9 4.4 to 6.7 2.1 to 3.5 2.5 to 3.4 8.43 3.33 3.78 0.52
Accuracy (dev.) (%) −14.0 to 1.7 0 to 5.9 2.2 to 10.2 2.3 to 3.3 −6.44 1.96 6.04 2.86
n 6 6 6 6 3 3 3 3
Table 3: Matrix effect.
Concentration (ng/ml)
TBM peak area (×104) IS peak area (×104) Ratio Matrix effect
Water M9 Water M9 Water M9 TBM IS Ratio
Low (120) 3.60± 0.12 3.83± 0.13 8.26± 0.49 8.72± 0.53 0.436 0.439 106 106 101
Medium (1500) 18.1± 1.0 20.0± 1.4 8.80± 0.77 9.30± 0.91 2.06 2.15 110 106 104
High (17000) 378± 5 413± 18 13.7± 0.5 14.7± 0.7 27.6 28.1 109 107 102
Data represent the mean peak area (±SD) from triplicate analysis.
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even smaller, suggesting that IS compensated the matrix
effect.
3.2.4. Partial Sample Volume Accuracy. As the target Cmax
is 40000 ng/mL, we evaluated accuracy of the assay with an
extrahigh QC (40000 ng/mL) when half sample volume was
used. ,e precision and accuracy from six replicates of
analysis were 2.2% and 2.6%, respectively. ,erefore, sam-
ples above the upper limit of quantification could be ana-
lyzed with a partial volume.
3.2.5. Stability. TBM was stable in M9 medium. No sig-
nificant degradation was found under tested condition
(Table 4). Further investigation is ongoing to define long-
term stability in −70°C freezer.
Table 4: Stability of TBM.
Conditions % remained RSD (%) n
In autosampler vial, 21–25°C, 3 days
300 ng/mL 107 3.5 3
20000 ng/mL 105 2.4 3
In M9, 21–25°C, 5 days
300 ng/mL 104 8.1 3
20000 ng/mL 99.2 3.6 3
3 freeze-thaw cycles
300 ng/mL 99.4 5.0 3
20000 ng/mL 99.8 2.4 3
In M9 medium, 6 days, −70°C
300 ng/mL 93.8 3.3 3
20000 ng/mL 101 3.0 3
IS (5000 ng/mL) in water 102.9 0.74 3
24 hr, 21–25°C 74.2 3.4 3
5 days, 21–25°C 79.5 1.7 4
Table 5: Interference of potential concomitant drugs.
Concentration (ng/mL) Control Colistin-MP∗ % dev.
150 150± 10 148± 8 −1.3
1500 1633± 61 1587± 98 −2.8
20000 20000± 557 19933± 737 −0.3
Note. Data represent the mean (SD) of triplicate analysis. ∗MP and colistin concentrations were 110 µg/mL and 20 µg/mL, respectively, corresponding to the
highest concentrations in the in vitro model.
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Figure 4: Concentration-time profile of tobramycin from an in vitro PK/PD biofilmmodel. Samples were taken from the feeding bottle (M)
and the tubing outlets from three flow cells with bacterial biofilm (F1, F2, and F3) at designated time intervals.
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3.2.6. Evaluation of Concomitant Drug Interference. ,e
samples from the supported study are expected to contain
MP and colistin; therefore, impact of these drugs on
quantification of TBM was evaluated. In the presence of
110 µg/mL MP and 20 µg/mL colistin, the low, medium, and
high QC samples could still be quantified accurately, with
a small percent deviation from the samples without these
drugs (Table 5).
3.3.Application. ,emethod was applied to determine TBM
concentrations used in an in vitro PK/PD biofilm simulator.
,e PK/PD analysis was reported elsewhere [15]. A repre-
sentative concentration-time curve from the model is
showed in Figure 4. ,e results demonstrate that the sen-
sitivity of the method met the requirement of the intended
study.
4. Conclusion
TCA not only improves peak shape and retention time of
TBM but also increases MS signal intensity of TBM. Using
a simple dilution with ion pairing reagent TCA, a sensitive
LC-MS/MS method was developed and validated for de-
termination of TBM in bacterial M9medium.,e LLOQwas
50 ng/mL.,e sensitivity of the assay met the requirement of
the intended PK/PD study in an in vitro biofilm model
system.
TCA has been used to increase retention time and
sensitivity for quantification of gentamicin, kanamycin, and
apramycin [14]. Here, we demonstrated application of TCA
to quantification of TBM. We speculate this approach could
be generalized: by addition of ion-pairing agents to samples
instead of adding to mobile phase solvents, we could extend
the retention time of analytes and even increase sensitivity.
Acidic ion-pairing agents such as TFA and TCA could be
applied to basic polar analytes such as amine-containing
analytes, and basic ion-pairing agents could be added to
samples of acidic polar analytes. Nevertheless, the concen-
tration of the ion-pairing agent is critical, and selection of
the ion-pairing agent is also critical.
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